

(English Translation of Consolidated Financial Statements and Report Originally Issued in Chinese)

BIOTEQUE CORPORATION AND SUBSIDIARIES

Consolidated Financial Statements

**With Independent Auditors' Review Report
For the Three Months Ended March 31, 2026 and 2025**

Address: 5F.-6, No.23, Sec.1. Chang-An E. Rd., Taipei City 104, Taiwan (R.O.C.)
Telephone: +886-2-2571-0269

The independent auditors' review report and the accompanying consolidated financial statements are the English translation of the Chinese version prepared and used in the Republic of China. If there is any conflict between, or any difference in the interpretation of the English and Chinese language independent auditors' review report and consolidated financial statements, the Chinese version shall prevail.

Table of contents

Contents	Page
1. Cover Page	1
2. Table of Contents	2
3. Independent Auditors' Review Report	3
4. Consolidated Balance Sheets	4
5. Consolidated Statements of Comprehensive Income	5
6. Consolidated Statements of Changes in Equity	6
7. Consolidated Statements of Cash Flows	7
8. Notes to the Consolidated Financial Statements	
(1) Company history	8
(2) Approval date and procedures of the consolidated financial statements	8
(3) New standards, amendments and interpretations adopted	8~10
(4) Summary of material accounting policies	10~11
(5) Significant accounting assumptions and judgments, and major sources of estimation uncertainty	11
(6) Explanation of significant accounts	11~31
(7) Related-party transactions	31
(8) Assets Pledged as security	32
(9) Commitments and contingencies	32
(10) Losses Due to Major Disasters	32
(11) Subsequent Events	32
(12) Other	32
(13) Other disclosures	
(a) Information on significant transactions	33~34
(b) Information on investees	35
(c) Information on investment in mainland China	35
(14) Segment information	35



安侯建業聯合會計師事務所
KPMG

台北市110615信義路5段7號68樓(台北101大樓)
68F., TAIPEI 101 TOWER, No. 7, Sec. 5,
Xinyi Road, Taipei City 110615, Taiwan (R.O.C.)

電話 Tel + 886 2 8101 6666
傳真 Fax + 886 2 8101 6667
網址 Web kpmg.com/tw

Independent Auditors' Review Report

To the Board of Directors of Bioteque Corporation:

Introduction

We have reviewed the accompanying consolidated balance sheets of Bioteque Corporation (the “Company”) and its subsidiaries (together referred to as the “Group”) as of March 31, 2026 and 2025, and the related consolidated statements of comprehensive income, changes in equity and cash flows for the three months ended March 31, 2026 and 2025, and notes to the consolidated financial statements, including a summary of significant accounting policies. Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and International Accounting Standard 34, “Interim Financial Reporting” endorsed and issued into effect by the Financial Supervisory Commission of the Republic of China. Our responsibility is to express a conclusion on the consolidated financial statements based on our reviews.

Scope of Review

We conducted our reviews in accordance with the Standard on Review Engagements 2410, “Review of Financial Information Performed by the Independent Auditor of the Entity” of the Republic of China. A review of the consolidated financial statements consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing of the Republic of China and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Conclusion

Based on our reviews, nothing has come to our attention that causes us to believe that the accompanying consolidated financial statements do not present fairly, in all material respects, the consolidated financial position of Bioteque Corporation and its subsidiaries as of March 31, 2026 and 2025, and of its consolidated financial performance and its consolidated cash flows for the three months ended March 31, 2026 and 2025 in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and International Accounting Standard 34, “Interim Financial Reporting” endorsed and issued into effect by the Financial Supervisory Commission of the Republic of China.



The engagement partners on the reviews resulting in this independent auditors' review report are Cheng, Po-Jen and Huang, Ming-Hung.

KPMG

Taipei, Taiwan (Republic of China)

May 8, 2026

Notes to Readers

The accompanying consolidated financial statements are intended only to present the consolidated statement of financial position, financial performance and cash flows in accordance with the accounting principles and practices generally accepted in the Republic of China and not those of any other jurisdictions. The standards, procedures and practices to review such consolidated financial statements are those generally accepted and applied in the Republic of China.

The independent auditors' review report and the accompanying consolidated financial statements are the English translation of the Chinese version prepared and used in the Republic of China. If there is any conflict between, or any difference in the interpretation of the English and Chinese language independent auditors' review report and consolidated financial statements, the Chinese version shall prevail.

(English Translation of Consolidated Financial Statements Originally Issued in Chinese)

BIOTEQUE CORPORATION AND SUBSIDIARIES**Consolidated Balance Sheets****March 31, 2026, December 31, 2025 and March 31, 2025****(Expressed in Thousands of New Taiwan Dollars)**

Assets		March 31, 2026		December 31, 2025		March 31, 2025		Liabilities and Equity		March 31, 2026		December 31, 2025		March 31, 2025	
		Amount	%	Amount	%	Amount	%			Amount	%	Amount	%	Amount	%
Current assets:								Current liabilities:							
1100	Cash and cash equivalents (note 6(a))	\$ 1,189,689	25	1,160,650	25	1,235,827	26	2100	Short-term borrowings (note 6(h))	\$ 15,806	-	-	-	-	-
	Current financial assets at fair value through profit or loss (note 6(b))	122,524	3	122,077	3	120,734	3	2130	Current contract liabilities (note 6(n))	52,073	1	47,746	1	66,779	2
1136	Current financial assets at amortized cost (note 6(c))	484,500	10	384,200	8	395,122	8	2150	Notes payable	96	-	131	-	538	-
1150	Notes receivable, net (notes 6(d) and (n))	94,794	2	78,816	2	76,885	2	2170	Accounts payable	120,217	3	106,583	2	91,691	2
1170	Accounts receivable, net (notes 6(d) and (n))	218,121	4	243,683	5	192,807	4	2209	Other payables (notes 6(j) and (o))	152,177	4	153,670	4	144,611	3
130X	Inventories (note 6(e))	299,839	6	294,358	6	306,513	6	2213	Payable on machinery and equipment	6,219	-	7,334	-	5,169	-
1476	Other current financial assets (note 8)	601	-	601	-	601	-	2216	Dividends payable (notes 6(l) and 7)	381,141	8	-	-	346,492	7
1479	Other current assets	47,369	1	48,315	1	35,942	1	2230	Current tax liabilities	105,814	2	66,891	2	114,483	3
	Total current assets	<u>2,457,437</u>	<u>51</u>	<u>2,332,700</u>	<u>50</u>	<u>2,364,431</u>	<u>50</u>	2280	Current lease liabilities (note 6(i))	14,901	-	14,852	-	7,660	-
Non-current assets:								2322	Long-term borrowings, current portion (note 6(h))	114,250	3	143,137	3	154,800	3
1600	Property, plant and equipment (notes 6(f) and 9)	1,949,230	41	1,936,901	42	2,033,169	43	2399	Other current liabilities	9,855	-	6,321	-	9,448	-
1755	Right-of-use assets (note 6(g))	339,913	7	343,329	7	337,459	7		Total current liabilities	<u>972,549</u>	<u>21</u>	<u>546,665</u>	<u>12</u>	<u>941,671</u>	<u>20</u>
1840	Deferred tax asset	3,668	-	3,668	-	3,691	-		Non-Current liabilities:						
1915	Prepayments for business facilities (note 9)	39,558	1	29,656	1	23,874	-	2541	Long-term borrowings (note 6(h))	104,729	2	153,292	4	253,979	5
1980	Other non-current financial assets	4,195	-	4,137	-	4,330	-	2570	Deferred tax liabilities	56,705	1	56,705	1	49,035	1
1995	Other non-current assets	11,861	-	9,608	-	6,375	-	2580	Non-current lease liabilities (note 6(i))	282,274	6	286,102	6	283,559	6
	Total non-current assets	<u>2,348,425</u>	<u>49</u>	<u>2,327,299</u>	<u>50</u>	<u>2,408,898</u>	<u>50</u>	2640	Net defined benefit liability, non-current	9,884	-	10,063	-	8,177	-
									Total non-current liabilities	<u>453,592</u>	<u>9</u>	<u>506,162</u>	<u>11</u>	<u>594,750</u>	<u>12</u>
									Total liabilities	<u>1,426,141</u>	<u>30</u>	<u>1,052,827</u>	<u>23</u>	<u>1,536,421</u>	<u>32</u>
									Equity attributable to owners of parent (note 6(l)):						
								3100	Ordinary shares	692,983	14	692,983	15	692,983	14
								3200	Capital surplus	317,117	7	317,117	7	317,029	7
									Retained earnings:						
								3310	Legal reserve	609,767	13	609,767	13	556,910	12
								3350	Unappropriated retained earnings	1,731,888	36	1,968,051	42	1,617,368	34
										<u>2,341,655</u>	<u>49</u>	<u>2,577,818</u>	<u>55</u>	<u>2,174,278</u>	<u>46</u>
									Other equity:						
								3410	Exchange differences on translation of foreign financial statements	27,966	-	19,254	-	52,618	1
									Total equity	<u>3,379,721</u>	<u>70</u>	<u>3,607,172</u>	<u>77</u>	<u>3,236,908</u>	<u>68</u>
Total assets		<u>\$ 4,805,862</u>	<u>100</u>	<u>4,659,999</u>	<u>100</u>	<u>4,773,329</u>	<u>100</u>	Total liabilities and equity		<u>\$ 4,805,862</u>	<u>100</u>	<u>4,659,999</u>	<u>100</u>	<u>4,773,329</u>	<u>100</u>

See accompanying notes to consolidated financial statements.

(English Translation of Consolidated Financial Statements Originally Issued in Chinese)

BIOTEQUE CORPORATION AND SUBSIDIARIES

Consolidated Statements of Comprehensive Income

For the three months ended March 31, 2026 and 2025

(Expressed in Thousands of New Taiwan Dollars, Except for Earnings Per Share)

		For the three months ended March 31			
		2026		2025	
		Amount	%	Amount	%
4000	Operating revenue (note 6(n))	\$ 546,438	100	518,563	100
5000	Operating costs (notes 6(e), (f), (g), (j) and 12)	299,404	55	293,865	57
	Gross profit from operations	<u>247,034</u>	<u>45</u>	<u>224,698</u>	<u>43</u>
6000	Operating expenses (notes 6(f), (g), (i), (j), (o), 7 and 12):				
6100	Selling expenses	21,432	4	21,901	4
6200	Administrative expenses	28,457	5	25,437	5
6300	Research and development expenses	21,132	4	18,242	3
	Total operating expenses	<u>71,021</u>	<u>13</u>	<u>65,580</u>	<u>12</u>
6900	Net operating income	<u>176,013</u>	<u>32</u>	<u>159,118</u>	<u>31</u>
7000	Non-operating income and expenses (notes 6(i) and (p)):				
7100	Interest income	3,473	-	4,088	1
7010	Other income	514	-	1,897	-
7020	Other gains and losses	5,656	1	7,561	1
7050	Finance costs	(1,684)	-	(1,956)	-
	Total non-operating income and expenses	<u>7,959</u>	<u>1</u>	<u>11,590</u>	<u>2</u>
7900	Profit before tax	183,972	33	170,708	33
7951	Less: Tax expenses (note 6(k))	38,994	7	36,175	7
	Profit	<u>144,978</u>	<u>26</u>	<u>134,533</u>	<u>26</u>
8300	Other comprehensive income (loss) (note (l)):				
8360	Components of other comprehensive income (loss) that will be reclassified to profit or loss:				
8361	Exchange differences on translation	8,712	2	7,900	1
8399	Income tax related to components of other comprehensive income that will be reclassified to profit or loss	-	-	-	-
	Total components of other comprehensive income (loss) that will be reclassified to profit or loss	<u>8,712</u>	<u>2</u>	<u>7,900</u>	<u>1</u>
8300	Other comprehensive income (loss), net	<u>8,712</u>	<u>2</u>	<u>7,900</u>	<u>1</u>
	Comprehensive income	<u>\$ 153,690</u>	<u>28</u>	<u>142,433</u>	<u>27</u>
9750	Basic earnings per share (note 6(m)) (Expressed in New Taiwan Dollars)	<u>\$ 2.09</u>		<u>1.94</u>	
9850	Diluted earnings per share (note 6(m)) (Expressed in New Taiwan Dollars)	<u>\$ 2.08</u>		<u>1.93</u>	

See accompanying notes to consolidated financial statements.

(English Translation of Consolidated Financial Statements Originally Issued in Chinese)

BIOTEQUE CORPORATION AND SUBSIDIARIES**Consolidated Statements of Changes in Equity****For the three months ended March 31, 2026 and 2025****(Expressed in Thousands of New Taiwan Dollars)**

	Attributable to owners of parent				Other equity Exchange differences on translation of foreign financial statements	Total equity
	Ordinary shares	Capital surplus	Legal reserve	Unappropriated retained earnings		
Balance at January 1, 2025	\$ 692,983	317,032	556,910	1,829,327	44,718	3,440,970
Net income for the three months ended March 31, 2025	-	-	-	134,533	-	134,533
Other comprehensive income for the three months ended March 31, 2025	-	-	-	-	7,900	7,900
Total comprehensive income for the three months ended March 31, 2025	-	-	-	134,533	7,900	142,433
Appropriation and distribution of retained earnings:						
Cash dividends	-	-	-	(346,492)	-	(346,492)
Change in capital surplus	-	(3)	-	-	-	(3)
Balance at March 31, 2025	\$ 692,983	317,029	556,910	1,617,368	52,618	3,236,908
Balance at January 1, 2026	\$ 692,983	317,117	609,767	1,968,051	19,254	3,607,172
Net income for the three months ended March 31, 2026	-	-	-	144,978	-	144,978
Other comprehensive income for the three months ended March 31, 2026	-	-	-	-	8,712	8,712
Total comprehensive income for the three months ended March 31, 2026	-	-	-	144,978	8,712	153,690
Appropriation and distribution of retained earnings:						
Cash dividends	-	-	-	(381,141)	-	(381,141)
Balance at March 31, 2026	\$ 692,983	317,117	609,767	1,731,888	27,966	3,379,721

See accompanying notes to consolidated financial statements.

(English Translation of Consolidated Financial Statements Originally Issued in Chinese)

BIOTEQUE CORPORATION AND SUBSIDIARIES**Consolidated Statements of Cash Flows****For the three months ended March 31, 2026 and 2025****(Expressed in Thousands of New Taiwan Dollars)**

	For the three months ended March 31	
	2026	2025
Cash flows generated from (used in) operating activities:		
Profit before tax	\$ 183,972	170,708
Adjustments:		
Adjustments to reconcile profit (loss):		
Depreciation expenses	42,266	41,200
Amortization expenses	1,477	978
Net gains on financial assets at fair value through profit or loss	(447)	(454)
Interest expenses	1,684	1,956
Interest income	(3,473)	(4,088)
Total adjustments to reconcile profit	<u>41,507</u>	<u>39,592</u>
Changes in operating assets:		
Notes receivable	(15,978)	(1,415)
Accounts receivable	25,562	(150)
Inventories	(5,481)	14,188
Other current assets	1,715	(4,007)
Total changes in operating assets	<u>5,818</u>	<u>8,616</u>
Changes in operating liabilities:		
Current contract liabilities	4,327	9,237
Notes payable	(35)	249
Accounts payable	13,634	(22,856)
Other payables	(1,539)	4,295
Other current liabilities	3,534	2,207
Net defined benefit liability	(179)	-
Total changes in operating liabilities	<u>19,742</u>	<u>(6,868)</u>
Total changes in operating assets and liabilities	<u>25,560</u>	<u>1,748</u>
Total adjustments	<u>67,067</u>	<u>41,340</u>
Cash inflow generated from operations	251,039	212,048
Interest received	1,431	2,044
Income taxes paid	(71)	(340)
Net cash flows generated from operating activities	<u>252,399</u>	<u>213,752</u>
Cash flows generated from (used in) investing activities:		
Acquisition of financial assets at amortized cost	(334,500)	(361,579)
Proceeds from disposal of financial assets at amortized cost	234,200	205,670
Acquisition of property, plant and equipment	(39,721)	(12,445)
Increase in other financial assets	(58)	(675)
Increase in other non-current assets	(3,730)	(1,374)
Increase in prepayments for business facilities	(12,606)	(1,729)
Decrease in payables on machinery and equipment	(1,115)	(2,826)
Net cash used in investing activities	<u>(157,530)</u>	<u>(174,958)</u>
Cash flows generated from (used in) financing activities:		
Increase in short-term loans	15,806	-
Repayments of long-term borrowings	(77,450)	(37,450)
Payment of lease liabilities	(3,688)	(3,185)
Interest paid	(1,638)	(1,974)
Other financing activities	-	(3)
Net cash used in financing activities	<u>(66,970)</u>	<u>(42,612)</u>
Effect on exchange rate changes on cash and cash equivalents	<u>1,140</u>	<u>2,690</u>
Net increase (decrease) in cash and cash equivalents	<u>29,039</u>	<u>(1,128)</u>
Cash and cash equivalents at beginning of period	<u>1,160,650</u>	<u>1,236,955</u>
Cash and cash equivalents at end of period	<u>\$ 1,189,689</u>	<u>1,235,827</u>

See accompanying notes to consolidated financial statements.

(English Translation of Consolidated Financial Statements Originally Issued in Chinese)

BIOTEQUE CORPORATION AND SUBSIDIARIES

Notes to the Consolidated Financial Statements

March 31, 2026 and 2025

(Expressed in Thousands of New Taiwan Dollars Except for Earnings Per Share Information and Unless Otherwise Specified)

(1) Company history

Bioteque Corporation (“the Company”) was incorporated in November, 1991 in accordance with The Company Act and the other related laws and regulations.

The Company's stock was listed on Taipei Exchange on March 4, 2002.

The business operation of the Company and its subsidiaries (together referred to as “the Group”) are manufacturing, trading and selling of the medical consumables.

(2) Approval date and procedures of the consolidated financial statements:

The consolidated financial statements were authorized for issuance by the board of directors on May 8, 2026.

(3) New standards, amendments and interpretations adopted:

- (a) The impact of the IFRS Accounting Standards endorsed by the Financial Supervisory Commission, R.O.C. which have already been adopted.

The Group has initially adopted the following new amendments, which do not have a significant impact on its consolidated financial statements, from January 1, 2026:

- IFRS 17 “Insurance Contracts” and amendments to IFRS 17 “Insurance Contracts”
- Amendments to IFRS 9 and IFRS 7 “Amendments to the Classification and Measurement of Financial Instruments”
- Annual Improvements to IFRS Accounting Standards—Volume 11
- Amendments to IFRS 9 and IFRS 7 “Contracts Referencing Nature-dependent Electricity”

(Continued)

BIOTEQUE CORPORATION AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

- (b) The impact of IFRS Accounting Standards issued by IASB but not yet endorsed by the FSC

The following new and amended standards, which may be relevant to the Group, have been issued by the International Accounting Standards Board (IASB), but have yet to be endorsed by the FSC:

Standards or Interpretations	Content of amendment	Effective date per IASB
IFRS 18 “Presentation and Disclosure in Financial Statements”	<p>The new standard introduces three categories of income and expenses, two income statement subtotals and one single note on management performance measures. The three amendments, combined with enhanced guidance on how to disaggregate information, set the stage for better and more consistent information for users, and will affect all the entities.</p> <ul style="list-style-type: none"> ● A more structured income statement: under current standards, companies use different formats to present their results, making it difficult for investors to compare financial performance across companies. The new standard promotes a more structured income statement, introducing a newly defined ‘operating profit’ subtotal and a requirement for all income and expenses to be allocated between three new distinct categories based on a company’s main business activities. ● Management performance measures (MPMs): the new standard introduces a definition for management performance measures, and requires companies to explain in a single note to the financial statements why the measure provides useful information, how it is calculated and reconcile it to an amount determined under IFRS Accounting Standards. ● Greater disaggregation of information: the new standard includes enhanced guidance on how companies group information in the financial statements. This includes guidance on whether information is included in the primary financial statements or is further disaggregated in the notes. 	January 1, 2027 note: On September 25, 2025, the FSC issued a press release announcing that Taiwan will adopt IFRS 18 beginning in 2028. Entities that need to adopt the new standard earlier may do with the endorsement of the FSC.

(Continued)

BIOTEQUE CORPORATION AND SUBSIDIARIES

Notes to the Consolidated Financial Statements

The Group is evaluating the impact on its consolidated financial position and consolidated financial performance upon the initial adoption of the abovementioned standards or interpretations. The results thereof will be disclosed when the Group completes its evaluation.

The Group does not expect the following other new and amended standards, which have yet to be endorsed by the FSC, to have a significant impact on its consolidated financial statements:

- Amendments to IFRS 10 and IAS 28 “Sale or Contribution of Assets Between an Investor and Its Associate or Joint Venture”
- IFRS 19 “Subsidiaries without Public Accountability: Disclosures” and amendments to IFRS 19 “Subsidiaries without Public Accountability: Disclosures”
- Amendments to IAS 21 “Translation to a Hyperinflationary Presentation Currency”

(4) Summary of material accounting policies:

(a) Statement of compliance

These consolidated financial statements have been prepared in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers (hereinafter referred to as “the Regulations”) and IAS 34 “Interim Financial Reporting” which are endorsed and issued into effect by the Financial Supervisory Commission (hereinafter referred to as FSC). The consolidated financial statements do not include all of the information required by the Regulations and International Financial Reporting Standards, International Accounting Standards, IFRIC Interpretations and SIC Interpretations endorsed and issued into effect by the FSC (altogether referred to “IFRS Accounting Standards” endorsed by the FSC) for a complete set of the annual consolidated financial statements.

Except the following accounting policies mentioned below, the material accounting policies adopted in the consolidated financial statements are the same as those in the consolidated financial statement for the year ended December 31, 2025. For the related information, please refer to note 4 of the consolidated financial statements for the year ended December 31, 2025.

(b) Basis of consolidation

(i) List of subsidiaries in the consolidated financial statements:

Name of investor	Name of subsidiary	Principal activity	Shareholding			Note
			March 31, 2026	December 31, 2025	March 31, 2025	
The Company	BIOTEQUE MEDICAL PHIL. INC.	Manufacturing and Trading of Medical equipment	100.00 %	100.00 %	100.00 %	
BIOTEQUE MEDICAL PHIL. INC.	BONTEQ MEDICAL DISTRIBUTION PHIL. INC.	Trading of Medical equipment	100.00 %	100.00 %	100.00 %	

(ii) List of subsidiaries which are not included in the consolidated financial statements: None.

(Continued)

BIOTEQUE CORPORATION AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

(c) Income taxes

The income tax expenses have been prepared and disclosed in accordance with paragraph B12 of IAS 34 “Interim Financial Reporting” .

Income tax expenses for the period are measured by multiplying together the pre-tax income for the interim reporting period and the management’s best estimate of effective annual tax rate. This should be recognized fully as tax expense for the current period.

Temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and their respective tax bases shall be measured based on the tax rates that have been enacted or substantively enacted at the time of the asset or liability is recovered or settled, and be recognized directly in equity or other comprehensive income as tax expense.

(d) Employee benefits

The pension cost in the interim period was calculated and disclosed on a year-to-date basis by using the actuarially determined pension cost rate at the end of the prior fiscal year.

(5) Significant accounting assumptions and judgments, and major sources of estimation uncertainty:

The preparation of the consolidated financial statements in conformity with the Regulations and IAS 34 “Interim Financial Reporting” endorsed by the FSC requires management to make judgments, and estimates about the future, including climate-related risks and opportunities, that affect the application of the accounting policies and the reported amount of assets, liabilities, income and expenses. Actual results may differ from these estimates.

The preparation of the consolidated interim financial statements, estimates and underlying assumptions are reviewed on an ongoing basis which are in conformity with the consolidated financial statements for the year ended December 31, 2025.

(6) Explanation of significant accounts:

Except for the following disclosures, there is no significant difference as compared with those disclosed in the consolidated financial statements for the year ended December 31, 2025. Please refer to Note 6 of the 2025 annual consolidated financial statements.

(a) Cash and cash equivalents

	March 31, 2026	December 31, 2025	March 31, 2025
Cash on hand	\$ 678	1,078	1,225
Cash in bank	<u>1,189,011</u>	<u>1,159,572</u>	<u>1,234,602</u>
Cash and cash equivalents in the consolidated statement of cash flows	<u><u>\$ 1,189,689</u></u>	<u><u>1,160,650</u></u>	<u><u>1,235,827</u></u>

(Continued)

BIOTEQUE CORPORATION AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

(b) Current financial assets at fair value through profit or loss

	March 31, 2026	December 31, 2025	March 31, 2025
Mandatorily measured at fair value through profit or loss:			
Non-derivative financial assets			
Money market funds and bond funds	\$ <u>122,524</u>	<u>122,077</u>	<u>120,734</u>

(i) For credit risk and market risk, please refer to note 6(q).

(ii) The financial assets of the Group were not collateralized.

(c) Current financial assets measured at amortized cost

	March 31, 2026	December 31, 2025	March 31, 2025
Time deposits	\$ <u>484,500</u>	<u>384,200</u>	<u>395,122</u>

The Group has assessed that these financial assets are held-to-maturity to collect contractual cash flows, which consist solely of payments of principal and interest on principal amount outstanding. Therefore, these investments were classified as financial assets measured at amortized cost.

(i) For the three months ended March 31, 2026 and 2025, the Group held time deposits, with weighted-average interest rates of 1.53%~1.66% and 1.53%~4.50%, respectively, which mature in April to August of 2026 and April to June of 2025, respectively.

(ii) For credit risk, please refer to note 6(q).

(iii) The financial assets of the Group were not collateralized.

(d) Notes and accounts receivables

	March 31, 2026	December 31, 2025	March 31, 2025
Notes receivable	\$ 94,794	78,816	76,885
Accounts receivables	<u>218,121</u>	<u>243,683</u>	<u>192,807</u>
	<u>\$ 312,915</u>	<u>322,499</u>	<u>269,692</u>

(Continued)

BIOTEQUE CORPORATION AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

	March 31, 2025		
	Gross carrying amount	Weighted- average loss rate	Loss allowance
Current	\$ 265,101	-	-
1 to 30 days past due	4,574	-	-
31 to 60 days past due	-	-	-
61 to 90 days past due	9	-	-
91 to 120 days past due	8	-	-
121 to 150 days past due	-	-	-
151 to 180 days past due	-	-	-
More than 181 days past due	-	100%	-
	\$ 269,692		-

The allowance for impairment remained unchanged for the three months ended March 31, 2026 and March 31, 2025, and the balance of the allowance for impairment as of March 31, 2026 and March 31, 2025 were both \$0.

The notes and accounts receivables of the Group were not collateralized.

For further credit risk information, please refer to note 6(q).

(e) Inventories

	March 31, 2026	December 31, 2025	March 31, 2025
Raw materials	\$ 160,659	169,819	151,466
Work in progress	50,419	50,116	65,980
Finished goods	43,668	46,780	45,433
Merchandise	12,317	14,039	17,651
Inventories in transit	32,776	13,604	25,983
	\$ 299,839	294,358	306,513

Except for cost of goods sold and inventories recognized as operating cost, the remaining gains or losses which were recognized as operating cost or deduction of operating cost were as follows:

	For the three months ended March 31, 2026	For the three months ended March 31, 2025
Gains on physical inventory	\$ (8)	(113)
Unallocated production overheads	21,735	22,141
Losses on valuation of inventories	630	3,790
	\$ 22,357	25,818

The inventories of the Group were not collateralized.

(Continued)

BIOTEQUE CORPORATION AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

(f) Property, plant and equipment

The cost and accumulated depreciation of the property, plant and equipment of the Group for the three months ended March 31, 2026 and 2025 were as follows:

	<u>Land</u>	<u>Building and structures</u>	<u>Machinery and equipment</u>	<u>Transportation equipment</u>	<u>Office equipment</u>	<u>Other equipment</u>	<u>Construction in progress</u>	<u>Total</u>
Cost:								
Balance at January 1, 2026	\$ 91,834	2,025,476	1,045,906	14,033	47,092	289,260	1,277	3,514,878
Additions	-	-	1,254	-	674	1,633	36,160	39,721
Disposals	-	-	(776)	-	-	(260)	-	(1,036)
Reclassification (Note 1)	-	-	1,702	-	-	3,561	(1,286)	3,977
Effect on changes in foreign exchange rates	-	6,969	2,982	50	54	1,562	420	12,037
Balance at March 31, 2026	<u>\$ 91,834</u>	<u>2,032,445</u>	<u>1,051,068</u>	<u>14,083</u>	<u>47,820</u>	<u>295,756</u>	<u>36,571</u>	<u>3,569,577</u>
Balance at January 1, 2025	\$ 91,834	2,041,818	1,025,860	13,997	39,721	263,867	-	3,477,097
Additions	-	-	7,742	-	651	3,079	973	12,445
Reclassification (Note 1)	-	-	17,766	-	2,839	2,575	-	23,180
Effect on changes in foreign exchange rates	-	4,807	1,999	34	33	1,046	9	7,928
Balance at March 31, 2025	<u>\$ 91,834</u>	<u>2,046,625</u>	<u>1,053,367</u>	<u>14,031</u>	<u>43,244</u>	<u>270,567</u>	<u>982</u>	<u>3,520,650</u>
Accumulated depreciation and impairment loss:								
Balance at January 1, 2026	\$ -	428,204	855,591	11,185	27,587	255,410	-	1,577,977
Depreciation	-	13,796	16,760	272	1,674	5,578	-	38,080
Disposals	-	-	(776)	-	-	(260)	-	(1,036)
Effect on changes in foreign exchange rates	-	1,444	2,309	39	41	1,493	-	5,326
Balance at March 31, 2026	<u>\$ -</u>	<u>443,444</u>	<u>873,884</u>	<u>11,496</u>	<u>29,302</u>	<u>262,221</u>	<u>-</u>	<u>1,620,347</u>
Balance at January 1, 2025	\$ -	376,048	799,947	10,177	21,947	238,452	-	1,446,571
Depreciation	-	13,879	16,985	290	1,312	5,123	-	37,589
Effect on changes in foreign exchange rates	-	893	1,401	24	26	977	-	3,321
Balance at March 31, 2025	<u>\$ -</u>	<u>390,820</u>	<u>818,333</u>	<u>10,491</u>	<u>23,285</u>	<u>244,552</u>	<u>-</u>	<u>1,487,481</u>
Carrying amounts:								
Balance at January 1, 2026	<u>\$ 91,834</u>	<u>1,597,272</u>	<u>190,315</u>	<u>2,848</u>	<u>19,505</u>	<u>33,850</u>	<u>1,277</u>	<u>1,936,901</u>
Balance at March 31, 2026	<u>\$ 91,834</u>	<u>1,589,001</u>	<u>177,184</u>	<u>2,587</u>	<u>18,518</u>	<u>33,535</u>	<u>36,571</u>	<u>1,949,230</u>
Balance at January 1, 2025	<u>\$ 91,834</u>	<u>1,665,770</u>	<u>225,913</u>	<u>3,820</u>	<u>17,774</u>	<u>25,415</u>	<u>-</u>	<u>2,030,526</u>
Balance at March 31, 2025	<u>\$ 91,834</u>	<u>1,655,805</u>	<u>235,034</u>	<u>3,540</u>	<u>19,959</u>	<u>26,015</u>	<u>982</u>	<u>2,033,169</u>

(Note 1) Prepayments for business facilities or construction in progress were reclassified as property, plant and equipment.

As of March 31, 2026, December 31 and March 31, 2025, the property, plant and equipment of the Group had not been pledged as collateral.

(Continued)

BIOTEQUE CORPORATION AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

(g) Right-of-use assets

The Group leases land and buildings. Information about leases for which the Group has been a lessee is presented below:

	<u>Land</u>	<u>Buildings and structures</u>	<u>Total</u>
Cost:			
Balance at January 1, 2026	\$ 377,375	20,807	398,182
Effect on changes in foreign exchange rates	<u>958</u>	<u>(112)</u>	<u>846</u>
Balance at March 31, 2026	<u>\$ 378,333</u>	<u>20,695</u>	<u>399,028</u>
Balance at January 1, 2025	\$ 380,494	31,837	412,331
Effect on changes in foreign exchange rates	<u>82</u>	<u>36</u>	<u>118</u>
Balance at March 31, 2025	<u>\$ 380,576</u>	<u>31,873</u>	<u>412,449</u>
Accumulated depreciation:			
Balance at January 1, 2026	\$ 49,351	5,502	54,853
Depreciation	2,329	1,857	4,186
Effect on changes in foreign exchange rates	<u>99</u>	<u>(23)</u>	<u>76</u>
Balance at March 31, 2026	<u>\$ 51,779</u>	<u>7,336</u>	<u>59,115</u>
Balance at January 1, 2025	\$ 41,402	30,462	71,864
Depreciation	2,337	1,274	3,611
Effect on changes in foreign exchange rates	<u>(521)</u>	<u>36</u>	<u>(485)</u>
Balance at March 31, 2025	<u>\$ 43,218</u>	<u>31,772</u>	<u>74,990</u>
Carrying amount:			
Balance at January 1, 2026	<u>\$ 328,024</u>	<u>15,305</u>	<u>343,329</u>
Balance at March 31, 2026	<u>\$ 326,554</u>	<u>13,359</u>	<u>339,913</u>
Balance at January 1, 2025	<u>\$ 339,092</u>	<u>1,375</u>	<u>340,467</u>
Balance at March 31, 2025	<u>\$ 337,358</u>	<u>101</u>	<u>337,459</u>

(h) Short-term and long-term borrowings

(i) Short-term borrowings

	<u>March 31, 2026</u>	<u>December 31, 2025</u>	<u>March 31, 2025</u>
Unsecured bank loans	<u>\$ 15,806</u>	<u>-</u>	<u>-</u>
Unused credit lines	<u>\$ 635,822</u>	<u>668,973</u>	<u>770,257</u>
Range of interest rate	<u>6.50%</u>	<u>-</u>	<u>-</u>

(Continued)

BIOTEQUE CORPORATION AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

(ii) Long-term borrowings

	March 31, 2026	December 31, 2025	March 31, 2025
Unsecured bank loans	\$ 218,979	296,429	408,779
Less: Current portion	<u>114,250</u>	<u>143,137</u>	<u>154,800</u>
Unsecured long-term borrowings	<u>\$ 104,729</u>	<u>153,292</u>	<u>253,979</u>
Unused credit lines	<u>\$ 150,000</u>	<u>150,000</u>	<u>150,000</u>
Range of interest rate	<u>1.38%~1.98%</u>	<u>1.38%~1.98%</u>	<u>1.38%~1.45%</u>

As of March 31, 2026, the details of the future repayment periods and amounts of the Group's long-term borrowings were as follows:

Period	Amount
2026.04.01~2027.03.31	\$ 114,250
2027.04.01~2028.03.31	<u>104,729</u>
	<u>\$ 218,979</u>

(iii) The Group has not pledged any assets as collateral for borrowing and credited lines.

(i) Lease liabilities

	March 31, 2026	December 31, 2025	March 31, 2025
Current	<u>\$ 14,901</u>	<u>14,852</u>	<u>7,660</u>
Non-current	<u>\$ 282,274</u>	<u>286,102</u>	<u>283,559</u>

For the maturity analysis, please refer to note 6(q).

The amounts recognized in profit or loss were as follows:

	For the three months ended March 31, 2026	For the three months ended March 31, 2025
Interest on lease liabilities	<u>\$ 605</u>	<u>440</u>
Expenses relating to leases of low-value assets	<u>\$ 16</u>	<u>22</u>

The amounts recognized in the statement of cash flows by the Group were as follows:

	For the three months ended March 31, 2026	For the three months ended March 31, 2025
Total cash outflow for leases	<u>\$ 4,309</u>	<u>3,647</u>

(Continued)

BIOTEQUE CORPORATION AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

For the three months ended March 31, 2026 and March 31, 2025, the Group leases land, buildings and structures for its office space, warehouse and parking lot . The leases run for a period of 2 to 20 years. Some leases include an option to renew the lease for an additional period of 2 to 20 years after the end of the contract term.

Some leases of equipment contain extension options exercisable. These leases are negotiated and monitored by local management, and accordingly, contain a wide range of different terms and conditions. The extension options held are exercisable only by the Group and not by the lessors. In which leasee is not reasonably certain to use an optional extended lease term, payments associated with the optional period are not included within lease liabilities.

(j) Employee benefits

(i) Defined benefit plans

Management believes that there was no material volatility of the market, no material reimbursement and settlement or other material one time events since prior fiscal year. As a result, the pension cost in the accompanying interim period was measured and disclosed according to the actuarial report as of December 31, 2025 and 2024.

The expenses recognized in profit or loss for the Group were as follows:

	For the Three months ended March 31, 2026	For the Three months ended March 31, 2025
Operating costs	\$ 75	76
Operating expenses	<u>1,436</u>	<u>198</u>
	<u>\$ 1,511</u>	<u>274</u>

(ii) Defined contribution plans

The pension costs incurred from the contributions to the Bureau of the Labor Insurance were as follow:

	For the Three months ended March 31, 2026	For the Three months ended March 31, 2025
Operating costs	\$ 1,481	1,479
Operating expenses	<u>857</u>	<u>799</u>
	<u>\$ 2,338</u>	<u>2,278</u>

(Continued)

BIOTEQUE CORPORATION AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

- (iii) The Group's subsidiaries incorporated in the Philippine have a defined contribution plan, wherein a monthly contribution to an independent fund, administered by the government in accordance with the pension regulations in the Republic of the Philippines, are based on certain percentage of employees' monthly salaries and wages. The Group recognized the pension costs were as follows:

	For the Three months ended March 31, 2026	For the Three months ended March 31, 2025
Operating costs	\$ 49	56
Operating expenses	26	33
	<u>\$ 75</u>	<u>89</u>

- (k) Income taxes

The amounts of income tax were as follows:

	For the Three months ended March 31, 2026	For the Three months ended March 31, 2025
Current tax expenses	<u>\$ 38,994</u>	<u>36,175</u>

The Company's income tax returns for all years through 2024 were assessed by the tax authorities.

- (l) Capital and other equity

Except for the following disclosure, there was no significant change for capital and other equity for the periods from January 1 to March 31, 2026 and 2025. For the related information, please refer to note 6(l) of the consolidated financial statements for the year ended December 31, 2025.

- (i) Capital surplus

Balances of capital surplus at the reporting date were as follows:

	March 31, 2026	December 31, 2025	March 31, 2025
Share capital	\$ 315,168	315,168	315,168
Donation from shareholders	1,949	1,949	1,861
	<u>\$ 317,117</u>	<u>317,117</u>	<u>317,029</u>

According to the R.O.C. Company Act, capital surplus can only be used to offset a deficit, and only the realized capital surplus can be used to increase the common stock or be distributed as cash dividends. The aforementioned realized capital surplus includes capital surplus resulting from premium on issuance of capital stock and earnings from donated assets received. According to the Regulations Governing the Offering and Issuance of Securities by Securities Issuers, capital increases by transferring capital surplus in excess of par value should not exceed 10% of the total common stock outstanding.

(Continued)

BIOTEQUE CORPORATION AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

(ii) Retained earnings

The Company's Articles of Incorporation stipulate that 10% of the annual income or earnings, after deducting any accumulated deficit, shall be set aside as a legal reserve. When the balance of such legal reserve reaches an amount equal to the paid-in capital, the appropriation to legal reserves is discontinued. If there are surplus profits remaining, at least 20% shall be allocated for distribution of shareholder dividends. The Board of Directors drafts a dividend distribution proposal and submits it to the shareholders meeting for resolution, in which cash dividends should make up at least 20% or more.

The Company should distribute dividends, bonuses, and capital reserves with cash. Distribution of dividends shall be undertaken by a resolution adopted by a majority vote at a Board meeting attended by at least two-thirds of the total number of directors, and a report of such distribution shall be submitted to the shareholders' meeting.

Because the industry the Company is involved in is undergoing a steady period of growth, the conditions, amount, and type of dividends mentioned in the preceding articles can be adjusted in response to the shifting market conditions and industry changes. In the mean time, the Company should consider the sustainable development and capital needs.

1) Legal reserve

When a company incurs no loss, it may, pursuant to a resolution by a shareholders' meeting, distribute its legal reserve by issuing new shares or by distributing cash, and only the portion of legal reserve which exceeds 25% of capital may be distributed.

2) Special reserve

In accordance with Ruling No. 1010012865 issued by the FSC on April 6, 2012, a portion of current-period earnings and undistributed prior-period earnings shall be reclassified as special earnings reserve during earnings distribution. The amount to be reclassified should equal the current-period total net reduction of other shareholders' equity. Similarly, a portion of undistributed prior-period earnings shall be reclassified as special earnings reserve (which does not qualify for earnings distribution) to account for cumulative changes to other shareholders' equity pertaining to prior periods. The amounts of subsequent reversals pertaining to the net reduction of other shareholders' equity shall qualify for additional distributions.

(Continued)

BIOTEQUE CORPORATION AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

3) Earnings distribution

The Board of Directors resolved on March 5, 2026 and March 6, 2025 respectively, to distribute the profits for the years 2025 and 2024. These earnings were appropriated as follows:

	2025		2024	
	Amount per share (NTD)	Amount	Amount per share (NTD)	Amount
Dividends distributed to ordinary shareholders:				
Cash	\$ 5.50	\$ <u><u>381,141</u></u>	5.00	<u><u>346,492</u></u>

(iii) Other equity

	Exchange differences on translation of foreign financial statements
Balance at January 1, 2026	\$ 19,254
Exchange differences on foreign operations	<u>8,712</u>
Balance at March 31, 2026	<u><u>\$ 27,966</u></u>
	Exchange differences on translation of foreign financial statements
Balance at January 1, 2025	\$ 44,718
Exchange differences on foreign operations	<u>7,900</u>
Balance at March 31, 2025	<u><u>\$ 52,618</u></u>

(m) Earnings per share

The Company's earnings per share were calculated as follows:

(i) Basic earnings per share

	For the Three months ended March 31, 2026	For the three months ended March 31, 2025
Profit attributable to ordinary shareholders of the Company	\$ <u><u>144,978</u></u>	<u><u>134,533</u></u>
Weighted-average number of ordinary shares (in thousand shares)	\$ <u><u>69,298</u></u>	<u><u>69,298</u></u>
Basic earnings per share (express in New Taiwan Dollars)	\$ <u><u>2.09</u></u>	<u><u>1.94</u></u>

(Continued)

BIOTEQUE CORPORATION AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

(ii) Diluted earnings per share

	For the three months ended March 31, 2026	For the three months ended March 31, 2025
Profit attributable to ordinary shareholders of the Company	<u>\$ 144,978</u>	<u>134,533</u>
Weighted-average number of ordinary shares (basic) (in thousand shares)	69,298	69,298
Effect on employee remuneration (in thousand shares)	<u>344</u>	<u>269</u>
Weighted-average number of ordinary shares (diluted) (in thousand shares)	<u>69,642</u>	<u>69,567</u>
Diluted earnings per share (express in New Taiwan Dollars)	<u>\$ 2.08</u>	<u>1.93</u>

(n) Revenue from contracts with customers

(i) Disaggregation of revenue

	For the Three months ended March 31, 2026	For the Three months ended March 31, 2025
Primary geographical markets:		
Asia	\$ 255,847	258,468
South Americas	43,739	30,787
North Americas	105,437	75,288
Others	<u>141,415</u>	<u>154,020</u>
Total	<u>\$ 546,438</u>	<u>518,563</u>
Major products service lines:		
Manufacturing, trading and selling of medical consumables	<u>\$ 546,438</u>	<u>518,563</u>

(ii) Contract balances

	March 31, 2026	December 31, 2025	March 31, 2025
Notes and accounts receivable	\$ 312,915	322,499	269,692
Less: allowance for impairment	<u>-</u>	<u>-</u>	<u>-</u>
Total	<u>\$ 312,915</u>	<u>322,499</u>	<u>269,692</u>
	March 31, 2026	December 31, 2025	March 31, 2025
Current contract liabilities	<u>\$ 52,073</u>	<u>47,746</u>	<u>66,779</u>

For details on notes and accounts receivable and allowance for impairment, please refer to note 6(d).

(Continued)

BIOTEQUE CORPORATION AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

The amount of revenue recognized for the three months ended March 31, 2026 and March 31, 2025 that was included in the contract liability balance at the beginning of the period were \$42,645 thousand \$53,341 thousand, respectively.

The major change in the balance of contract assets and liabilities is the difference between the time frame in the performance obligation to be satisfied and the payment to be received.

(o) Remuneration to employees and directors

On June 19, 2025, the Company resolved at the shareholders' meeting to amend its Articles of Incorporation. According to the amended Articles, if the Company has profit in a given fiscal year, more than 5% of the profits shall be allocated as employees' remuneration and salaries adjustment to those base-level employees and no more than 1.6% of the profits shall be allocated as directors' remuneration. Prior to the amendments, the Article of Incorporation stipulated that, if the Company has profit in a given fiscal year, no less than 5% shall be allocated as employee's remuneration and no more than 1.6% shall be allocated as directors' remuneration. However, if there are any accumulated losses of the Company, the Company shall pre-reserve the amount to offset the loss.

The Company's estimated remuneration is as follows:

	For the Three months ended March 31, 2026	For the Three months ended March 31, 2025
Employees' remuneration	\$ 10,463	9,002
Directors' remuneration	3,118	2,908
	<u>\$ 13,581</u>	<u>11,910</u>

The amount of employees' remuneration, and directors' remuneration were estimated based on profit before tax, net of the amount of the remuneration, and multiplied by the rule of Company's Article of Association. The above remuneration were included in the operating expenses of the three months ended March 31, 2026 and March 31, 2025. The differences between the actual distributed amounts as determined by the Board of Directors and those recognized in the financial statements, if any, shall be accounted for as changes in accounting estimates and recognized in profit or loss in the following year.

The remunerations to employees amounted to \$42,254 thousand and \$35,687 thousand, respectively, for the years ended the us and December 31, 2025 and 2024. The remunerations to directors amounted to \$11,489 thousand and \$11,420 thousand, respectively, for the years ended December 31, 2025 and 2024.

There was no difference between the actual distributed amounts as determined by the Board of Directors and those recognized in the financial statement for the years of 2025 and 2024.

The related information mentioned above can be found on websites such as the Market Observation Post System.

(Continued)

BIOTEQUE CORPORATION AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

(p) Non-operating income and expenses

(i) Interest income

	For the Three months ended March 31, 2026	For the Three months ended March 31, 2025
Interest income:		
Interest income from deposit	\$ 6	5
Interest income from bank deposit	<u>3,467</u>	<u>4,083</u>
	<u>\$ 3,473</u>	<u>4,088</u>

(ii) Other income

	For the Three months ended March 31, 2026	For the Three months ended March 31, 2025
Subsidy revenue	\$ 34	756
Rent revenue	87	68
Others	<u>393</u>	<u>1,073</u>
	<u>\$ 514</u>	<u>1,897</u>

(iii) Other gains and losses

	For the Three months ended March 31, 2026	For the Three months ended March 31, 2025
Foreign exchange gains	\$ 5,325	7,200
Gains on financial assets at fair value through profit or loss	447	454
Others	<u>(116)</u>	<u>(93)</u>
	<u>\$ 5,656</u>	<u>7,561</u>

(iv) Finance costs

	For the Three months ended March 31, 2026	For the Three months ended March 31, 2025
Interest expense on bank borrowings	\$ 1,079	1,516
Interest expense on lease liabilities	<u>605</u>	<u>440</u>
	<u>\$ 1,684</u>	<u>1,956</u>

(Continued)

BIOTEQUE CORPORATION AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

(q) Financial instruments

Except for the content mentioned below, there was no significant change in the fair value of the Group's financial instruments and degree of exposure to credit risk, liquidity risk and market risk arising from financial instruments. For the related information please refer to note 6(q) of the consolidated financial statements for the year ended December 31, 2025. Regarding how the financial instruments are considered to have low credit risk, please refer to note 4(g) of the consolidated financial statements for the year ended December 31, 2025.

(i) Credit risk

1) Credit risk exposure

The carrying amount of financial assets represents the maximum amount exposed to credit risk.

As of March 31, 2026, December 31, 2025 and March 31, 2025, 38%, 20% and 41% of the Group's notes and accounts receivable were concentrated on three, one and three specific customers respectively. Accordingly, concentrations of credit risk exist.

2) Receivables securities

For credit risk exposure of notes and trade receivables, please refer to note 6(d).

Other financial assets at amortized cost are mainly time deposits. These financial assets are considered to have low risk, and thus, the impairment provision recognized during the period was limited to 12 months expected losses. For the correlated credit risk, please refer to note 6(d).

(ii) Liquidity risk

The following table shows the contractual maturities of financial liabilities, including estimated interest payments and excluding the impact of netting agreements.

	<u>Carrying amount</u>	<u>Contractual cash flows</u>	<u>1 year</u>	<u>1-2 years</u>	<u>2-5 years</u>	<u>Over 5 years</u>
March 31, 2026						
Non-derivative financial liabilities						
Notes payable	\$ 96	96	96	-	-	-
Accounts payable	120,217	120,217	120,217	-	-	-
Other payables	152,177	152,177	152,177	-	-	-
Payables on machinery and equipment	6,219	6,219	6,219	-	-	-
Dividends payable	381,141	381,141	381,141	-	-	-
Lease liabilities (current and non-current)	297,175	328,163	17,140	13,994	30,137	266,892
Long-term borrowings (including current portion)	218,979	220,464	115,380	105,084	-	-
Short-term borrowings	15,806	15,933	15,933	-	-	-
	<u>\$ 1,191,810</u>	<u>1,224,410</u>	<u>808,303</u>	<u>119,078</u>	<u>30,137</u>	<u>266,892</u>

(Continued)

BIOTEQUE CORPORATION AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

	<u>Carrying amount</u>	<u>Contractual cash flows</u>	<u>1 year</u>	<u>1-2 years</u>	<u>2-5 years</u>	<u>Over 5 years</u>
December 31, 2025						
Non-derivative financial liabilities						
Notes payable	\$ 131	131	131	-	-	-
Accounts payable	106,583	106,583	106,583	-	-	-
Other payables	153,670	153,670	153,670	-	-	-
Payables on machinery and equipment	7,334	7,334	7,334	-	-	-
Lease liabilities (current and non-current)	300,954	332,562	17,167	15,389	30,793	269,213
Long-term borrowings (including current portion)	296,429	298,625	144,691	134,876	19,058	-
	<u>\$ 865,101</u>	<u>898,905</u>	<u>429,576</u>	<u>150,265</u>	<u>49,851</u>	<u>269,213</u>
March 31, 2025						
Non-derivative financial liabilities						
Notes payable	\$ 538	538	538	-	-	-
Accounts payable	91,691	91,691	91,691	-	-	-
Other payables	144,611	144,611	144,611	-	-	-
Payables on machinery and equipment	5,169	5,169	5,169	-	-	-
Dividends payable	346,492	346,492	346,492	-	-	-
Lease liabilities (current and non-current)	291,219	322,694	9,386	9,283	27,850	276,175
Long-term borrowings (including current portion)	408,779	412,597	156,904	135,564	120,129	-
	<u>\$ 1,288,499</u>	<u>1,323,792</u>	<u>754,791</u>	<u>144,847</u>	<u>147,979</u>	<u>276,175</u>

The Group does not expect the cash flows included in the maturity analysis to occur significantly earlier or at significantly different amount.

(iii) Market risk

1) Currency risk

The Group's significant exposure to foreign currency risk was as follows:

	<u>March 31, 2026</u>			<u>December 31, 2025</u>			<u>March 31, 2025</u>		
	<u>Foreign currency (in thousands)</u>	<u>Exchange rate</u>	<u>NTD</u>	<u>Foreign currency (in thousands)</u>	<u>Exchange rate</u>	<u>NTD</u>	<u>Foreign currency (in thousands)</u>	<u>Exchange rate</u>	<u>NTD</u>
Financial assets									
<u>Monetary items</u>									
USD	\$ 9,316	32.00	298,121	8,899	31.42	279,608	8,120	33.18	269,433
EUR	962	36.72	35,311	676	36.90	24,962	1,503	35.94	54,036
JPY	39,351	0.20	7,898	33,532	0.20	6,735	29,641	0.22	6,600
PHP	183,092	0.53	96,714	197,158	0.53	105,381	198,524	0.58	115,640
CNY	15,887	4.63	73,572	17,102	4.50	76,891	14,324	4.57	65,489
<u>Investments accounted for using equity method</u>									
USD	16,790	32.00	537,293	16,585	31.42	521,115	15,738	33.18	522,187
PHP	142,006	0.53	75,011	129,998	0.53	69,484	142,944	0.58	83,265
Financial liabilities									
<u>Monetary items</u>									
USD	2,562	32.00	81,973	2,387	31.42	75,006	2,119	33.18	70,305
EUR	141	36.72	5,172	303	36.90	11,170	183	35.94	6,568
JPY	50,592	0.20	10,154	19,829	0.20	3,983	37,991	0.22	8,459
PHP	18,361	0.53	9,699	13,363	0.53	7,143	15,388	0.58	8,963

(Continued)

BIOTEQUE CORPORATION AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

The Group's exposure to foreign currency risk arise from the translation of the foreign currency exchange gains and losses on cash and cash equivalents, accounts receivables, other receivables, accounts payable, other payables and payables on machinery and equipment that are denominated in foreign currency.

A depreciation (appreciation) of 1% of the NTD against the foreign currency for the three months ended March 31, 2026 and March 31, 2025, would have increased (decreased), the net profit before tax by \$4,046 thousand \$4,169 thousand, respectively. The analysis is performed on the same basis for 2025.

Since the Group has many kinds of functional currencies, the information on foreign exchange gain (loss) on monetary items is disclosed by total amount. For the three months ended March 31, 2026 and March 31, 2025, foreign exchange gains (including realized and unrealized portions) amounted to \$5,325 thousand \$7,200 thousand, respectively.

2) Interest rate analysis

Please refer to the notes on liquidity risk management and interest rate exposure of the Group's financial assets and liabilities.

The following sensitivity analysis is based on the exposure to the interest rate risk of non-derivative financial instruments on the reporting date. Regarding assets with variable interest rates, the analysis is based on the assumption that the amount of assets outstanding at the reporting date was outstanding throughout the year. The rate of change is expressed as the interest rate increases or decreases by 1% when reporting to management internally, which also represents the Group management's assessment of the reasonably possible interest rate change.

If the interest rate had increased / decreased by 1% basic points, the Group's net profit before tax would have decreased / increased by \$587 thousand \$1,022 thousand for the three months ended March 31, 2026 and March 31, 2025, respectively, with all other variable factors remain constant. This is mainly due to the Group's borrowing at floating rates.

3) Other market price risk

For the three months ended March 31, 2026 and March 31, 2025, the sensitivity analyzes for the changes in the securities price at the reporting date were performed using the same basis for the profit and loss as illustrated below:

	For the three months ended March 31			
	2026		2025	
Prices of securities at the reporting date	Other comprehensive income before tax	Net profit before tax	Other comprehensive income before tax	Net profit before tax
Increasing 1%	\$ -	1,225	-	1,207
Decreasing 1%	\$ -	(1,225)	-	(1,207)

(Continued)

BIOTEQUE CORPORATION AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

	March 31, 2025				
	Book value	Fair value			Total
		Level 1	Level 2	Level 3	
Financial assets at fair value through profit or loss					
Non-derivative financial assets mandatorily measured at fair value through profit or loss	\$ 120,734	120,734	-	-	120,734
Financial assets measured at amortized cost					
Cash and cash equivalents	1,235,827	-	-	-	-
Financial assets measured at amortized cost	395,122	-	-	-	-
Receivables	269,692	-	-	-	-
Other financial assets	4,931	-	-	-	-
Subtotal	1,905,572	-	-	-	-
Total	\$ 2,026,306	120,734	-	-	120,734
Financial liabilities measured at amortized cost					
Notes and accounts payable	\$ 92,229	-	-	-	-
Other payables	144,611	-	-	-	-
Payables on machinery and equipment	5,169	-	-	-	-
Dividends payable	346,492	-	-	-	-
Long-term borrowings (including current portion)	408,779	-	-	-	-
Lease liabilities (current and non-current)	291,219	-	-	-	-
Total	\$ 1,288,499	-	-	-	-

2) Valuation techniques for financial instruments measured at fair value

A financial instrument is regarded as being quoted in an active market if quoted prices are readily and regularly available from an exchange, dealer, broker, industry group, pricing service, or regulatory agency and those prices represent actual and regularly occurring market transactions on an arm's-length basis. Whether transactions are taking place 'regularly' is a matter of judgment and depends on the facts and circumstances of the market for the instrument.

Quoted market prices may not be indicative of the fair value of an instrument if the activity in the market is infrequent, the market is not well-established, only small volumes are traded, or bid-ask spreads are very wide. Determining whether a market is active involves judgment.

When the financial instruments of the Group are traded in an active market, its fair value is illustrated by the category and nature as follows:

The fair value of listed stocks and funds traded in an active market is based on the market quoted price.

Measurements of fair value of financial instruments without an active market are based on valuation technique or quoted price from a competitor. Fair value, measured by using valuation technique that can be extrapolated from either similar financial instruments or discounted cash flow method or other valuation techniques, including models, is calculated based on available market data at the reporting date.

(Continued)

BIOTEQUE CORPORATION AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

3) Categories and fair values of financial instruments

The Group strives to use market observable inputs when measuring assets and liabilities. Different levels of the fair value hierarchy to be used in determining the fair value of financial instruments are as follows:

- a) Level 1: quoted prices (unadjusted) in active markets for identical assets or liabilities.
- b) Level 2: inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices).
- c) Level 3: inputs for the assets or liability that are not based on observable market data (unobservable inputs).

For the three months ended March 31, 2026 and March 31, 2025, there were no changes on the fair value hierarchy of financial asset.

(r) Financial risk management

There were no significant changes in the Group's financial risk management and policies as disclosed in note 6(r) of the consolidated financial statements for the year ended December 31, 2025.

(s) Capital management

Management believes that the objectives, policies and processes of capital management of the Group have been applied consistently with those described in the consolidated financial statements for the year ended December 31, 2025. Also, management believes that there were no significant changes in the Group's capital management information as disclosed for the year ended December 31, 2025. Please refer to Note 6(s) of the consolidated financial statements for the year ended December 31, 2025 for further details.

(t) Investing and financing activities not affecting current cash flow

The Group's financial activities which did not affect the current cash flow for the three months ended March 31, 2026 and March 31, 2025 were as follows:

- (i) For right-of-use assets under leases, please refer to note 6(g).
- (ii) Reconciliation of liabilities arising from financial activities was as follows:

	January 1, 2026	Cash flows	<u>Non-cash changes</u>		March 31, 2026
			Foreign exchange movement	Other	
Short-term borrowings	\$ -	15,806	-	-	15,806
Long-term borrowings (including current portion)	296,429	(77,450)	-	-	218,979
Lease liabilities (current and non-current)	300,954	(3,688)	(91)	-	297,175
Total liabilities from financial activities	<u>\$ 597,383</u>	<u>(65,332)</u>	<u>(91)</u>	<u>-</u>	<u>531,960</u>

(Continued)

BIOTEQUE CORPORATION AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

	January 1, 2025	Cash flows	Non-cash changes		March 31, 2025
			Foreign exchange movement	Other	
Long-term borrowings (including current portion)	\$ 446,229	(37,450)	-	-	408,779
Lease liabilities (current and non-current)	294,404	(3,185)	-	-	291,219
Total liabilities from financial activities	<u>\$ 740,633</u>	<u>(40,635)</u>	<u>-</u>	<u>-</u>	<u>699,998</u>

(7) Related-party transactions:

(a) Names and relationship with the Group

Name	Relationship with the Group
Keyao Co., Ltd.	The entity has significant influence over the Group
Yide Co., Ltd.	Other related party
Yisheng Co., Ltd.	Other related party

(b) Significant transactions with related parties:

Payables to related parties

Payables to related parties of the Group were as follows :

Account	Class of related parties	March 31, 2026	December 31, 2025	March 31, 2025
Dividends payable	Significant Influencers-Keyao Co., Ltd.	\$ 38,478	-	34,980
Dividends payable	Others	26,637	-	24,215
		<u>\$ 65,115</u>	<u>-</u>	<u>59,195</u>

(c) Key management personnel compensation

Key management personnel compensation was comprised as below:

	For the Three months ended March 31, 2026	For the Three months ended March 31, 2025
Short-term employee benefits	\$ 7,321	7,047
Post-employment benefits	1,416	179
	<u>\$ 8,737</u>	<u>7,226</u>

(Continued)

BIOTEQUE CORPORATION AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

(8) Assets Pledged as security:

<u>Pledged assets</u>	<u>Pledged to secure</u>	<u>March 31, 2026</u>	<u>December 31, 2025</u>	<u>March 31, 2025</u>
Other current financial assets:				
Restricted bank deposit	Purchase guarantee	\$ <u>601</u>	<u>601</u>	<u>601</u>

(9) Commitments and contingencies:

(a) Notes issued as guarantee

	<u>March 31, 2026</u>	<u>December 31, 2025</u>	<u>March 31, 2025</u>
Bank borrowings and lease guarantee	\$ <u>1,720,333</u>	<u>1,918,593</u>	<u>1,923,873</u>

(b) The agreements for the purchases of machinery and equipment

	<u>March 31, 2026</u>	<u>December 31, 2025</u>	<u>March 31, 2025</u>
Total contract price	\$ <u>167,016</u>	<u>96,193</u>	<u>20,188</u>
Paid amount	\$ <u>26,811</u>	<u>20,102</u>	<u>10,783</u>

(10) Losses Due to Major Disasters: None**(11) Subsequent Events: None****(12) Other:**

A summary of employee benefits, depreciation, and amortization, by function, is as follows:

By item	For the Three months ended March 31, 2026			For the Three months ended March 31, 2025		
	By function Cost of sales	Operating expenses	Total	Cost of sales	Operating expenses	Total
Employee benefits						
Salary	61,644	31,625	93,269	59,471	29,308	88,779
Labor and health insurance	4,874	2,113	6,987	4,912	2,367	7,279
Pension	1,605	2,319	3,924	1,611	1,030	2,641
Remuneration of directors	-	3,118	3,118	-	2,908	2,908
Others	2,741	1,094	3,835	3,066	1,235	4,301
Depreciation	38,456	3,810	42,266	38,059	3,141	41,200
Amortization	1,077	400	1,477	485	493	978

(c) Seasonality of operations

The Group's operations were not affected by seasonality or cyclical factors.

(Continued)

BIOTEQUE CORPORATION AND SUBSIDIARIES

Notes to the Consolidated Financial Statements

(13) Other disclosures:

(a) Information on significant transactions:

The followings is the information on the Group's significant transactions required by the "Regulations Governing the Preparation of Financial Reports by Securities Issuers" for the three months ended March 31, 2026:

- (i) Loans to other parties: None.
- (ii) Guarantees and endorsements for other parties:

(In thousands of NTD and USD)

Number	Name of guarantor	Counterparty of guarantee and endorsement		Limitation on amount of guarantees and endorsements for a specific enterprise (Note 2)	Highest balance of guarantees and endorsements during the period	Balance of guarantees and endorsements as of reporting date	Actual usage amount	Property pledged for guarantees and endorsements (Amount)	Ratio of accumulated amounts of guarantees and endorsements to net worth of the latest financial statements	Maximum amount for guarantees and endorsements (Note 1)	Parent company endorsements/ guarantees to third parties on behalf of subsidiary	Subsidiary endorsements/ guarantees to third parties on behalf of parent company	Endorsements/ guarantees to third parties on behalf of companies in Mainland China
		Name	Relationship with the Company (Note 3)										
0	The Company	BIOTEQUE MEDICAL PHIL. INC.	2	207,894	96,000 (USD 3,000)	96,000 (USD 3,000)	15,806 USD 494	-	2.84 %	339,561	Y	N	N

Note 1: The total amount for the guarantees and endorsements provided by the Company to external entities shall not exceed 49% of the Company's shares. The total amount for the guarantees and endorsements provided by the Company and its subsidiaries to external entities shall not exceed 49% of the Company's net worth.

Note 2: The total amount for the guarantees and endorsements provided by the Company to any individual entity shall not exceed 30% of the Company's shares. The total amount for the guarantees and endorsements provided by the Company and its subsidiaries to any individual entity shall not exceed 30% of the Company's net worth.

Note 3: Relationship with the Company

1. Ordinary business relationship.
2. An entity, directly and indirectly, owned more than 50% voting shares of a guarantor.
3. A guarantor, directly and indirectly, owned more than 50% voting shares of an entity.
4. An entity, directly and indirectly, owned more than 90% voting shares of a guarantor.
5. Fulfillment of contractual obligations by providing mutual endorsements and guarantees for peer or joint builders in order to undertake a construction project.
6. An entity that is guaranteed and endorsed by all capital contributing shareholders in proportion to their shareholding percentages.
7. Peer engaged in the escrow of the sales contract on pre-sale house under the Consumer Protection Act.

(iii) Information regarding securities held at the reporting date (subsidiaries, associates and joint ventures not included):

(In thousands of NTD and shares)

Name of holder	Category and name of security	Relationship with company	Account title	Ending balance			Fair value	Remark
				Shares/Units (in thousands)	Carrying value	Percentage of ownership (%)		
The Company	Capital Money Market Fund	None	Current financial assets at fair value through profit or loss	641	10,980	- %	10,980	
"	Yuanta Wan Tai Money Market Fund	"	"	2,497	40,097	- %	40,097	
"	Franklin Templeton Sinoam Money Market Fund	"	"	2,992	32,888	- %	32,888	
"	Mega Diamond Money Market Fund	"	"	2,894	38,559	- %	38,559	
	Total				122,524		122,524	

(Continued)

BIOTEQUE CORPORATION AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

- (iv) Information regarding related-parties purchases and/or sales exceeding 100 million or 20% of the Company's paid-in capital: None.
- (v) Information regarding receivables from related-parties exceeding 100 million or 20% of the Company's paid-in capital:

(In thousands of New Taiwan Dollars)

Name of company	Related party	Nature of relationship	Ending balance	Turnover rate	Overdue		Amounts received in subsequent period	Allowance for bad debts
					Amount	Action taken		
The Company	BIOTEQUE MEDICAL PHIL. INC.	Subsidiary	162,055	1.43 %	-	-	3,881	-

Note: The amounts of the transaction and the ending balance had been offset in the consolidated financial statements.

- (vi) Significant transactions and business relationship between the parent company and its subsidiaries for the three months ended March 31, 2026:

(In thousands of New Taiwan Dollars)

No. (Note 1)	Name of company	Name of counter-party	Nature of relationship	Intercompany transactions			Percentage of the consolidated net revenue or total assets
				Account name	Amount	Trading terms	
0	The Company	BIOTEQUE MEDICAL PHIL. INC.	1	Accounts receivable	157,266	OA 270	3.27%
0	The Company	BIOTEQUE MEDICAL PHIL. INC.	1	Processing costs	12,364	There is no significant difference from translation terms with non-related parties.	2.26%
0	The Company	BIOTEQUE MEDICAL PHIL. INC.	1	Other receivables	4,789	OA 270	0.10%
0	The Company	BIOTEQUE MEDICAL PHIL. INC.	1	Accounts payable	48,105	OA 60	1.00%
0	The Company	BONTEQ MEDICAL DISTRIBUTION PHIL. INC.	1	Sales revenue	8,749	There is no significant difference from translation terms with non-related parties.	1.60%
0	The Company	BONTEQ MEDICAL DISTRIBUTION PHIL. INC.	1	Accounts receivable	9,647	OA 120	0.20%
1	BIOTEQUE MEDICAL PHIL. INC.	BONTEQ MEDICAL DISTRIBUTION PHIL. INC.	3	Other receivables	170	OA 30	-%
1	BIOTEQUE MEDICAL PHIL. INC.	BONTEQ MEDICAL DISTRIBUTION PHIL. INC.	3	Sales revenue	31,004	There is no significant difference from translation terms with non-related parties.	5.67%
1	BIOTEQUE MEDICAL PHIL. INC.	BONTEQ MEDICAL DISTRIBUTION PHIL. INC.	3	Accounts receivable	11,688	OA 30	0.24%

Note 1: Company numbering as follows:

Parent company—0

Subsidiary starts from 1

Note 2: The numbering of the relationship between transaction parties as follows:

Parent company to subsidiary—1

Subsidiary to parent company—2

Subsidiary to subsidiary—3

Note 3: The amounts of the transaction and the ending balance had been offset in the consolidated financial statements.

(Continued)

BIOTEQUE CORPORATION AND SUBSIDIARIES

Notes to the Consolidated Financial Statements

(b) Information on investees:

The following are the information on investees for the three months ended March 31, 2026 (excluding information on investees in Mainland China):

(In thousands of New Taiwan Dollars)

Name of investor	Name of investee	Location	Main businesses and products	Original investment amount		Balance as of March 31, 2026			Net income (losses) of investee	Share of profits (losses) of investee	Remark
				March 31, 2026	December 31, 2025	Shares (in thousands)	Percentage of ownership	Carrying value			
The Company	BIOTEQUE MEDICAL PHIL. INC.	Philippines	Manufacturing and Trading of Medical equipment	299,315	299,315	4,481	100 %	537,293	6,956	6,956	Subsidiary
BIOTEQUE MEDICAL PHIL. INC.	BONTEQ MEDICAL DISTRIBUTION PHIL. INC.	Philippines	Trading of Medical equipment	6,801	6,801	670	100 %	75,011	6,351	6,351	Sub-Subsidiary

Note 1: The amount of the transaction and the ending balance had been offset in the consolidated financial statements.

(c) Information on investment in mainland China: None.

(14) Segment information:

There were no significant changes in the Group's segment, as well as the profit and loss measurement basis, as disclosed in the consolidated financial statements for the year ended December 31, 2025.

The Group's operating segment information and reconciliation were as follows:

	For the Three months ended March 31, 2026					
	Segment A	Segment B	Segment C	Other Segments	Reconciliation and elimination	Total
Revenue:						
Revenue from external customers	\$ 155,009	118,647	257,112	15,670	-	546,438
Intersegment revenue	-	6,090	-	-	(6,090)	-
Total revenue	<u>\$ 155,009</u>	<u>124,737</u>	<u>257,112</u>	<u>15,670</u>	<u>(6,090)</u>	<u>546,438</u>
Reportable segment profit or loss	<u>\$ 22,114</u>	<u>36,236</u>	<u>135,686</u>	<u>(10,064)</u>	<u>-</u>	<u>183,972</u>
	For the Three months ended March 31, 2025					
	Segment A	Segment B	Segment C	Other Segments	Reconciliation and elimination	Total
Revenue:						
Revenue from external customers	\$ 152,102	101,855	247,791	16,815	-	518,563
Intersegment revenue	-	6,040	-	-	(6,040)	-
Total revenue	<u>\$ 152,102</u>	<u>107,895</u>	<u>247,791</u>	<u>16,815</u>	<u>(6,040)</u>	<u>518,563</u>
Reportable segment profit or loss	<u>\$ 19,525</u>	<u>24,727</u>	<u>137,299</u>	<u>(10,843)</u>	<u>-</u>	<u>170,708</u>

The material reconciling items of the above reportable segment are as below:

Total reportable segment revenue should eliminate intersegment revenue by \$6,090 thousand and \$6,040 thousand for the three months ended March 31, 2026 and 2025, respectively.